ACEing COVID-19: A Role For Angiotensin Axis Inhibition in SARS-CoV-2 infection
Department of Medicine, Division of Cardiovascular Medicine
Cardiology | Cardiovascular Diseases | Immunology and Infectious Disease | Infectious Disease | Virus Diseases
Cardiometabolic disease, especially hypertension, is a common risk factor for mortality among individuals with SARS-CoV-2 disease (COVID-19). The role of hypertension and vascular disease in COVID-19 has raised considerable debate around how to best manage anti-hypertensive therapy to alter disease trajectory. Given the role of the ACE2 receptor in SARS-CoV-2 viral entry6, angiotensin system modulation by ACE inhibitors (ACE-I) or angiotensin-II receptor blockers (ARBs) in clinical management have taken center stage in this controversy.
COVID-19, SARS-CoV-2, editorials, angiotensin II, hypertension, infections
DOI of Published Version
Murthy VL, Koupenova M, Shah RV. ACEing COVID-19: A Role for Angiotensin Axis Inhibition in SARS-CoV-2 Infection? Circ Res. 2020 Jun 5;126(12):1682-1684. doi: 10.1161/CIRCRESAHA.120.317174. Epub 2020 Apr 17. PMID: 32302248; PMCID: PMC7274880. Link to article on publisher's site
Shah R, Koupenova-Zamor M, Murthy VL. (2020). ACEing COVID-19: A Role For Angiotensin Axis Inhibition in SARS-CoV-2 infection. COVID-19 Publications by UMMS Authors. https://doi.org/10.1161/CIRCRESAHA.120.317174. Retrieved from https://escholarship.umassmed.edu/covid19/14